{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:48:11Z","timestamp":1792064891138,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":93,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-62249-0","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:48:13Z","timestamp":1784044093000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genotype analysis of Fabry disease in a Spanish at-risk population reveals 10 novel GLA variants"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1395-2356","authenticated-orcid":false,"given":"Jessica","family":"Ugalde-Altamirano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Josep","family":"Coll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna Priscila","family":"Reinoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaston Julio","family":"Pi\u00f1eiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cucchiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Iranzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Obach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Yag\u00fce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Corral-Velez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Campistol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose-Vicente","family":"Torregrosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"62249_CR1","doi-asserted-by":"crossref","unstructured":"Benjamin, E. R. et al. Co-administration with the pharmacological chaperone AT1001 increases recombinant human \u03b1-galactosidase A tissue uptake and improves substrate reduction in Fabry mice. Mol. Ther. 20(4), 717\u2013726. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22215019\/ (2012).","DOI":"10.1038\/mt.2011.271"},{"key":"62249_CR2","unstructured":"Desnick, R. J., Ioannou, Y. A. & Christine, M. Eng. The online metabolic and molecular bases of inherited disease. McGraw-Hill Education. \u03b1-galactosidase a deficiency: fabry disease | The Online Metabolic and Molecular Bases of Inherited Disease | OMMBID | McGraw Hill Medical. Available from: https:\/\/ommbid.mhmedical.com\/content.aspx?bookid=2709&sectionid=225546984 (2019)."},{"key":"62249_CR3","doi-asserted-by":"crossref","unstructured":"Mehta, A. et al. Review Fabry disease: a review of current management strategies. Q J. Med. 103, 641\u2013659. Available from: https:\/\/academic.oup.com\/qjmed\/article\/103\/9\/641\/1582452 (2010).","DOI":"10.1093\/qjmed\/hcq117"},{"key":"62249_CR4","doi-asserted-by":"crossref","unstructured":"Spada, M. et al. ARTICLE high incidence of later-onset fabry disease revealed by newborn screening. Am. J. Hum. Genet. 79, 31\u201340. Available from: www.ajhg.org (2005).","DOI":"10.1086\/504601"},{"key":"62249_CR5","doi-asserted-by":"crossref","unstructured":"Germain, D. P., Shabbeer, J., Cotigny, S. & Desnick, R. J. Fabry disease: twenty novel-galactosidase a mutations and genotype-phenotype correlations in classical and variant phenotypes. Mol. Med. 8(6), 306\u2013312. Available from: http:\/\/www.ncbi.nih.gov\/Entrez\/nucleotide.html (2002).","DOI":"10.1007\/BF03402156"},{"key":"62249_CR6","doi-asserted-by":"crossref","unstructured":"Shabbeer, J., Asuda, M., Enson, S. B., Esnick, R. D. & Fabrydisease Identification of 50 novel a-galactosidase Am utations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations. Hum Genomics . 2006 Mar;2(5):297-309. doi: 10.1186\/1479-7364-2-5-297.","DOI":"10.1186\/1479-7364-2-5-297"},{"key":"62249_CR7","doi-asserted-by":"crossref","unstructured":"Giacalone, I. et al. The identification of a novel pathogenic variant of the GLA gene associated with a classic phenotype of Anderson\u2013Fabry disease: a clinical and molecular study. Int. J. Mol. Sci. 26(2), 470. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11764866\/ (2025).","DOI":"10.3390\/ijms26020470"},{"key":"62249_CR8","doi-asserted-by":"publisher","unstructured":"Yao, F. et al. Long-read sequencing enables comprehensive molecular genetic diagnosis of Fabry disease. [cited 2025 Mar 13]; Available from: https:\/\/doi.org\/10.1186\/s40246-024-00697-3","DOI":"10.1186\/s40246-024-00697-3"},{"issue":"1","key":"62249_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1096\/fj.04-2375com","volume":"19","author":"GHF Yam","year":"2005","unstructured":"Yam, G. H. F., Zuber, C. & Roth, J. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder. FASEB J. 19 (1), 12\u201318 (2005).","journal-title":"FASEB J."},{"key":"62249_CR10","doi-asserted-by":"publisher","unstructured":"von Scheidt, W. et al. An atypical variant of Fabry\u2019s disease with manifestations confined to the myocardium. New Eng. J. Med. 324(6), 395\u2013399. Available from: https:\/\/www.nejm.org\/doi\/full\/https:\/\/doi.org\/10.1056\/NEJM199102073240607 (1991).","DOI":"10.1056\/NEJM199102073240607"},{"issue":"6","key":"62249_CR11","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.amjms.2020.07.011","volume":"360","author":"M Michaud","year":"2020","unstructured":"Michaud, M. et al. When and how to diagnose fabry disease in clinical pratice. Am. J. Med. Sci. 360 (6), 641\u2013649 (2020).","journal-title":"Am. J. Med. Sci."},{"key":"62249_CR12","doi-asserted-by":"crossref","unstructured":"Migeon, B. R. X inactivation, female mosaicism, and sex differences in renal diseases. J. Am. Soc. Nephrol. 19(11), 2052\u20132059. Available from: https:\/\/journals.lww.com\/jasn\/fulltext\/2008\/11000\/x_inactivation,_female_mosaicism,_and_sex.6.aspx (2008).","DOI":"10.1681\/ASN.2008020198"},{"key":"62249_CR13","doi-asserted-by":"crossref","unstructured":"Kotanko, P. et al. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J. Am. Soc. Nephrol. 15(5), 1323\u20131329. Available from: https:\/\/journals.lww.com\/jasn\/fulltext\/2004\/05000\/results_of_a_nationwide_screening_for.21.aspx (2004).","DOI":"10.1097\/01.ASN.0000124671.61963.1E"},{"key":"62249_CR14","unstructured":"Hag\u00e8ge, A. A. et al. Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: the FOCUS study on behalf of the FOCUS study investigators. [cited 2025 Mar 13]; Available from: http:\/\/heart.bmj.com\/"},{"key":"62249_CR15","doi-asserted-by":"publisher","unstructured":"Brouns, R. et al. Belgian fabry study: prevalence of fabry disease in a cohort of 1000 young patients with cerebrovascular disease. Stroke. 41(5), 863\u2013868. Available from: https:\/\/www.ahajournals.org\/doi\/https:\/\/doi.org\/10.1161\/STROKEAHA.110.579409 (2010).","DOI":"10.1161\/STROKEAHA.110.579409"},{"key":"62249_CR16","doi-asserted-by":"publisher","unstructured":"Rodr\u00edguez-Mar\u00ed, A., Coll, M. J. & Chab\u00e1s, A. Molecular analysis in Fabry disease in Spain: fifteen novel GLA mutations and identification of a homozygous female. Hum. Mutat. 22(3), 258\u2013258. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/full\/https:\/\/doi.org\/10.1002\/humu.9172 (2003).","DOI":"10.1002\/humu.9172"},{"key":"62249_CR17","unstructured":"Richards Chair, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. [cited 2025 Mar 15]; Available from: http:\/\/www.nature.com\/authors\/editorial_policies\/license.html#terms"},{"key":"62249_CR18","doi-asserted-by":"crossref","unstructured":"Reisin R, Perrin A, Garc\u00eda-Pav\u00eda P. Time delays in the diagnosis and treatment of Fabry disease. Int J Clin Pract. 2017 Jan;71(1). doi: 10.1111\/ijcp.12914. PMID: 28097762.","DOI":"10.1111\/ijcp.12914"},{"key":"62249_CR19","doi-asserted-by":"publisher","unstructured":"Hag\u00e8ge, A. et al. The French hypertrophic cardiomyopathy gene register: a systematic large gene screening for hypertrophic cardiomyopathy. Available from: https:\/\/doi.org\/10.1016\/j.ijcard.2024.132542 (2024).","DOI":"10.1016\/j.ijcard.2024.132542"},{"key":"62249_CR20","doi-asserted-by":"publisher","unstructured":"Vieitez, I. et al. Fabry disease in the Spanish population: observational study with detection of 77 patients. Orphanet. J. Rare Dis. 13(1), 1\u201313. Available from: https:\/\/ojrd.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s13023-018-0792-8 (2018).","DOI":"10.1186\/s13023-018-0792-8"},{"issue":"25","key":"62249_CR21","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/j.jacc.2007.09.022","volume":"50","author":"MJ Ackerman","year":"2007","unstructured":"Ackerman, M. J. & Landstrom, A. P. Detection of subclinical fabry disease in patients presenting with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 50 (25), 2404\u20132405 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"62249_CR22","doi-asserted-by":"publisher","unstructured":"Saito, O. et al. Prevalence of Fabry disease in dialysis patients: Japan Fabry disease screening study (J-FAST). Clin. Exp. Nephrol. 20(2), 284\u2013293. Available from: https:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s10157-015-1146-7 (2016).","DOI":"10.1007\/s10157-015-1146-7"},{"key":"62249_CR23","doi-asserted-by":"publisher","unstructured":"Turkmen, K. et al. The prevalence of Fabry disease in patients with chronic kidney disease in Turkey: the TURKFAB study. Kidney Blood Press. Res. 41(6), 1016\u20131024. Available from: https:\/\/doi.org\/10.1159\/000452605 (2016).","DOI":"10.1159\/000452605"},{"key":"62249_CR24","doi-asserted-by":"crossref","unstructured":"Elliott, P. et al. Prevalence of Anderson\u2013Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson\u2013Fabry disease survey. Heart. 97(23), 1957\u20131960. Available from: https:\/\/heart.bmj.com\/content\/97\/23\/1957 (2011).","DOI":"10.1136\/heartjnl-2011-300364"},{"key":"62249_CR25","doi-asserted-by":"publisher","unstructured":"Fazekas, F. et al. Brain magnetic resonance imaging findings fail to suspect fabry disease in young patients with an acute cerebrovascular event. Stroke. 46(6):1548\u20131553. Available from: https:\/\/www.ahajournals.org\/doi\/https:\/\/doi.org\/10.1161\/STROKEAHA.114.008548 (2015).","DOI":"10.1161\/STROKEAHA.114.008548"},{"key":"62249_CR26","doi-asserted-by":"crossref","unstructured":"Dubuc, V. et al. Prevalence of Fabry disease in young patients with cryptogenic ischemic stroke. J. Stroke Cerebrovasc. Dis. 22(8), 1288\u20131292. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23168217\/ (2013).","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.10.005"},{"key":"62249_CR27","first-page":"1186","volume":"3","author":"CM Eng","year":"1993","unstructured":"Eng, C. M., Resnick-Silverman, L. A., Niehaus, D. J., Astrin, K. H. & Desnick, R. J. Nature and frequency of mutations in the a-galactosidase a gene that cause fabry disease. Am. J. Hum. Genet. 3, 1186\u20131197 (1993).","journal-title":"Am. J. Hum. Genet."},{"key":"62249_CR28","doi-asserted-by":"crossref","unstructured":"Zizzo, C. et al. Systematic DNA study for fabry disease in the end stage renal disease patients from a southern italy area. Kidney Blood Press Res. 43(4), 1344\u20131351. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30099469\/ (2018).","DOI":"10.1159\/000492593"},{"key":"62249_CR29","doi-asserted-by":"crossref","unstructured":"Lukas, J. et al. Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease. PLoS Genet. 9(8), e1003632. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3731228\/ (2013).","DOI":"10.1371\/journal.pgen.1003632"},{"key":"62249_CR30","doi-asserted-by":"crossref","unstructured":"Lenders, M. et al. Multifocal white matter lesions associated with the D313Y mutation of the \u03b1-galactosidase a gene. PLoS One. 8(2), e55565. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3564750\/ (2013).","DOI":"10.1371\/journal.pone.0055565"},{"key":"62249_CR31","doi-asserted-by":"publisher","unstructured":"du Moulin, M. et al. The mutation p.D313Y is associated with organ manifestation in Fabry disease. Clin. Genet. 92(5), 528\u2013533. Available from: https:\/\/onlinelibrary-wiley-com.sire.ub.edu\/doi\/full\/https:\/\/doi.org\/10.1111\/cge.13007 (2017).","DOI":"10.1111\/cge.13007"},{"key":"62249_CR32","doi-asserted-by":"crossref","unstructured":"Koulousios, K. et al. Fabry disease due to D313Y and novel GLA mutations. BMJ Open. 7(10). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28988177\/ (2017).","DOI":"10.1136\/bmjopen-2017-017098"},{"key":"62249_CR33","doi-asserted-by":"crossref","unstructured":"Azevedo, O. et al. Founder effect of Fabry disease due to p.F113L mutation: clinical profile of a late-onset phenotype. Mol. Genet. Metab. 129(2), 150\u2013160. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31519519\/ (2020).","DOI":"10.1016\/j.ymgme.2019.07.012"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62249-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62249-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62249-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:56:09Z","timestamp":1792061769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62249-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["62249"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-62249-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is an observational study. The Research Ethics Committee of Hospital Cl\u00ednic de Barcelona confirmed that no formal ethical approval was required.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data were anonymized and analyzed in an aggregated manner; therefore, no individual consent for publication was required.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"32327"}}